COVID-19 in hemodialysis patients by Yaqub, Sonia et al.
eCommons@AKU 
Section of Nephrology Department of Medicine 
7-1-2021 




Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_nephrol 
 Part of the Diseases Commons, and the Nephrology Commons 
LETTER TO THE EDITOR




Patients  on  maintenance  hemodialysis  (HD)  are  commonly
affected with multiple comorbidities and are also prone to infec-
tions due to uremia-induced suppressed immunity, making them
more  vulnerable  to  COVID-19.1,2  The  altered  immune  state
together  with  associated  comorbidities  and  impractical  social
distancing due to inevitable frequent visits to dialysis unit poses
threat of severe COVID-19. The risk may further increase in HD
patients of low income countries due to lack of facilities and limita-
tion of implementation of epidemiologic measures for infection
control. Studies from various parts of the world have reported
varying  prevalence,  clinical  presentations  and  case  fatalities.
Prevalence ranging 2-28% with regional variations and a higher
mortality rate 14-51% has been observed compared to general
population.3-5  Moreover,  the  clinical  presentation  of  COVID-19
may range from asymptomatic to non-specific symptoms that
may be attributed to dialysis, such as shortness of breath or cough
from fluid overload and; hence, poses challenge in prompt diag-
nosis of disease in this group. There is limited information on symp-
toms, laboratory and radiologic abnormalities and outcomes of
COVID-19 in patients on HD from Pakistan.
We reviewed clinical presentation and short-term outcomes of
COVID-19 in patients on HD at our centre. Out of 108 patients,
13.9% (n=15) were affected by COVID-19. Mean age was 62.8 ±
8.6 years and 53.3% were females. Most common cause of kidney
failure  was  diabetic  kidney  disease  (80%;  n=12),  unknown
etiology (13.3%, n=2), chronic glomerulonephritis (6.7%, n=1).
Among comorbid conditions, hypertension was the most preva-
lent (100%), followed by diabetes mellitus (86.7%) and ischemic
heart disease (33.3%). One patient had chronic obstructive pulmo-
nary disease (COPD) and another had active malignancy; and was
on chemotherapeutic treatment. Forty percent of the patients
were asymptomatic. Among symptomatic patients, shortness of
breath was commonest (40%; n=6), followed by cough (26.7%;
n=4) and fever (20%; n=3). Half of the patients required hospitali-
sation; and more than two-thirds of those required invasive or
non-invasive ventilation. The mortality rate observed was 40%.
Compared  to  survivors,  deceased  patients  were  significantly
older and had higher inflammatory markers including C-reactive
protein,  ferritin,  procalcitonin,  lactate  dehydrogenase.
Lymphopenia, a universal finding in COVID-19, was not observed;
and only 40% patients had radiological findings consistent with
COVID-19 at the time of presentation.
Given the high mortality rates, patients on maintenance HD are
considered as a high-risk population for poor outcomes. A wide clin-
ical presentation and asymptomatic nature of disease in some
cases emphasise the need for high clinical suspicion as well as
implementation of proactive measures in screening and isolating
suspected cases. Effectively, prevention of the spread of infection
among HD centres, healthcare personnel, and patients is essen-
tial to ensure the safety of all stakeholders as well as continued
delivery of HD to patients.
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